摘要
目的探讨骨髓增生异常综合征(MDS)患者细胞遗传学及临床特征。方法回顾性分析2008—2012年根据美国和英国协作组(FAB)及世界卫生组织(WHO)标准诊断为MDS的112例患者。采用传统细胞遗传学(CG)及荧光原位杂交(FISH)研究其分子遗传学改变。根据国际预后积分系统(IPSS)标准对染色体核型进行分组,分为好、中等、差3组。结果 112例患者中具有克隆性染色体异常46例,占41.1%。核型"好"组50例(44.6%),"中等"组42例(37.5%),"差"组20例(17.9%)。中位生存期(MS)分别为59,43,12个月,P<0.01。结论染色体核型异常与预后存在显著相关性。
Objective To investigate the clinical cytogenetic features and prognosis of myelodysplastic syndrome. Methods A retrospective analysis was conducted on 112 patients diagnosed with MDS on basis of FAB and WHO criterion. Conventional cytogenetics and fluorescence in situ hybridization are performed to investigate the cytogenetic features. Results Karyotype abnormalities are found in 46 （41.1%） patients. Cytogenetics subgroups are divided into 3 groups according to IPSS criterion： good, intermediate, poor, which accounts for 44. 6%, 37.5 % ,47.9%, with a median survival time（MS） 59, 43, 12 months, respectively. Conclusion There is an obvious correlation between chromosomal abnormalities and MS.
基金
沈阳市血液病及肿瘤研究重点实验室建设项目(F10-218-1-00)
